Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.47 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.47 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2085500 | 0.86 | ATM (0.47) | ALDH1A1SMN1; SMN2PDE4DLMNAHPGD | |
| SCHEMBL4050492 | 0.85 | ALDH1A1 (0.59) | ALDH1A1TSHRSMN1; SMN2PDE4DLMNA | |
| SCHEMBL16317148 | 0.84 | ALDH1A1 (0.52) | ALDH1A1TSHRSMN1; SMN2PDE4DLMNA | |
| SCHEMBL2899043 | 0.83 | ALDH1A1 (0.56) | ALDH1A1TSHRSMN1; SMN2PDE4DLMNA | |
| SCHEMBL2081991 | 0.81 | ALDH1A1 (0.54) | ALDH1A1TSHRSMN1; SMN2PDE4DLMNA | |
| SCHEMBL2083765 | 0.80 | ALDH1A1 (0.53) | ALDH1A1TSHRSMN1; SMN2PDE4DLMNA | |
| SCHEMBL2082551 | 0.79 | SMN1; SMN2 (0.58) | ALDH1A1TSHRSMN1; SMN2LMNACYP1A2 | |
| SCHEMBL4704914 | 0.79 | PDE4D (0.52) | ALDH1A1TSHRSMN1; SMN2PDE4DLMNA | |
| SCHEMBL14357218 | 0.77 | KMT2A (0.55) | ALDH1A1TSHRSMN1; SMN2PDE4DLMNA | |
| SCHEMBL22122108 | 0.77 | HPGD (0.52) | ALDH1A1TSHRSMN1; SMN2LMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163756-B2 | For example,1-(3-t-butyl-1- (1,2,3,4-tetrahydro- isoquinolin-6-yl)-1H- pyrazol-5-yl)-3-(3- cyanophenyl)urea; for treatment of mammalian cancers and inflammatory diseases including rheumatoid arthritis, retinopathies | DECIPHERA PHARMACEUTICALS, LLC (US) | 2012-04-24 | — | — | US | disclosed |
| US-8163756-B2 | For example,1-(3-t-butyl-1- (1,2,3,4-tetrahydro- isoquinolin-6-yl)-1H- pyrazol-5-yl)-3-(3- cyanophenyl)urea; for treatment of mammalian cancers and inflammatory diseases including rheumatoid arthritis, retinopathies | DECIPHERA PHARMACEUTICALS, LLC (US) | 2012-04-24 | — | — | US | disclosed |
| US-20090312349-A1 | ANTI-INFLAMMATORY MEDICAMENTS | DECIPHERA PHARMACEUTICALS, LLC | 2009-12-17 | — | — | US | disclosed |
| US-20090312349-A1 | ANTI-INFLAMMATORY MEDICAMENTS | DECIPHERA PHARMACEUTICALS, LLC | 2009-12-17 | — | — | US | disclosed |
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-05-15 | — | — | US | disclosed |
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-05-15 | — | — | US | disclosed |
| US-20070191336-A1 | p38 kinase inhibitors | DECIPHERA PHARMACEUTICALS, LLC | 2007-08-16 | — | — | US | disclosed |
| US-20070191336-A1 | p38 kinase inhibitors | DECIPHERA PHARMACEUTICALS, LLC | 2007-08-16 | — | — | US | disclosed |
| US-20070078121-A1 | Enzyme modulators and treatments | DECIPHERA PHARMACEUTICALS, LLC | 2007-04-05 | — | — | US | disclosed |
| US-20070078121-A1 | Enzyme modulators and treatments | DECIPHERA PHARMACEUTICALS, LLC | 2007-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312349-A1 | ANTI-INFLAMMATORY MEDICAMENTS | ABL2, ABL1, PTK2 | ALDH1A1 1756/4885TSHR 4549/4885SMN1; SMN2 4040/4885 |
| US-20070191336-A1 | p38 kinase inhibitors | MAPK1, MAP3K8, MAP3K1 | ALDH1A1 3608/4885TSHR 4185/4885SMN1; SMN2 1101/4885 |
| US-20070078121-A1 | Enzyme modulators and treatments | ABL1, ABL2, LCK | ALDH1A1 1036/4885TSHR 3697/4885SMN1; SMN2 3782/4885 |
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | ABL2, BRAF, MAP3K1 | ALDH1A1 1274/4885TSHR 3699/4885SMN1; SMN2 2868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.